Ganglioneuroblastoma

Ganglioneuroblastoma (GN) is a rare malignant tumor that develops from neuroblasts, the early cells that predate nerve cells. This disease is most often observed in children, from the neonatal period to 5 years of age. The pathways of ganglioneuroblastoma formation are not yet fully understood, but it is known that this is a dopamine tumor that can affect both the adrenal glands and the sympathetic nervous system. Ganglioneuroblastoma can manifest itself with various clinical symptoms, including abdominal pain, abdominal enlargement, anemia, and weight loss. Due to the fact that the disease can be aggressive, early diagnosis and initiation of treatment are critical for successful control of the pathology.

History of the disease and interesting historical facts

The history of ganglioneuroblastoma as a separate clinical entity begins in the mid-20th century, when it began to stand out from more general categories of neuroblastomas. The first cases of this type of tumor were described in children, and numerous studies have been conducted since then. It is interesting that, unlike other childhood tumors, such as osteosarcoma, ganglioneuroblastoma was first noted as a separate form only in the 1970s, which allowed it to be isolated in clinical practice. It is also important to note that diagnostic and treatment methods have improved in recent decades, which has led to an increase in the survival rate of patients with this disease.

Epidemiology

Ganglioneuroblastoma is considered a rare disease, and its prevalence varies in different cases. In the total number of childhood tumors, it accounts for approximately 3-5% among all malignant neoplasms in children. According to statistics, the number of new cases is 1-2 cases per 100,000 live births per year. The disease is slightly more common in boys than in girls, with the greatest number of cases observed between the ages of 1 and 4 years.

Genetic predisposition to this disease

Research suggests a genetic predisposition to ganglioneuroblastoma. Certain mutations in genes involved in the wave structure of the nervous system may increase the risk, such as MYCN, ALK, and PHOX2B. This tumor may be associated with syndromes such as Down syndrome or Williams syndrome, indicating a possible link between chromosomal abnormalities and the development of the disease. Analysis of these genes helps in diagnosis and prognosis of the disease.

Risk factors for the development of this disease

Risk factors associated with ganglioneuroblastoma may include:

• Environmental factors such as exposure to chemicals (pesticides, herbicides) in pregnant women.
• A history of cancer in the family, which may indicate a hereditary predisposition.
• Infectious diseases during pregnancy, which increases the risk of birth defects in the fetus.
• Variations in chromosomes that can lead to oncogenesis, especially in the case of mutations in the MYCN and ALK genes.

Diagnosis of this disease

Diagnosis of ganglioneuroblastoma is based on clinical manifestations and a number of research methods:

• The main symptoms may include abdominal pain, abdominal distension, and possible symptoms of compression of nerve structures.
• Laboratory tests of blood and urine (especially for the presence of metanephrines), which may indicate specific adrenal activity.
• Radiological examinations such as ultrasound, CT and MRI allow detailed visualization of the tumor and assessment of its size and spread.
• Other diagnostic tests may include a biopsy for histologic analysis.
• Differential diagnosis is necessary to exclude other tumors such as neuroblastoma or adrenal pheochromocytoma.

Treatment

Treatment of ganglioneuroblastoma includes several approaches, which depend on the stage of the disease and the patient's condition:

• General treatment includes surgical resection of the tumor if possible.
• Pharmacological treatment may include chemotherapy, depending on the type and stage of the tumor.
• Surgical treatment involves removing the disease while preserving organs.
• Other treatments, such as radiation therapy, may be used if the cancer recurs or to shrink the tumor before surgery.

List of drugs used to treat this disease

Medicines used to treat ganglioneuroblastoma may include:

• Cisplatin
• Vincristine
• Doxorubicin
• Ifosfamide
• etoposide
• Topotecan

Disease monitoring

Monitoring of patients with ganglioneuroblastoma includes regular follow-up examinations:

• Examination should be carried out at regular intervals to detect relapses.
• Prognosis depends on the stage of the disease and treatment options; early diagnosis significantly improves outcomes.
• Complications may include metastasis and tumor recurrence, which require immediate intervention.

Age-related features of the disease

Ganglioneuroblastoma is most often seen in young children:

• Under 1 year of age: diagnosis is often made based on incidental findings during other examinations.
• From 1 to 4 years: symptoms become more obvious and the course of the disease can be most aggressive.
• At an older age: cases are rare, but cases with metastases of an initially undetected tumor are possible.

Questions and Answers

• What is ganglioneuroblastoma? - It is a malignant tumor that arises from early nerve cells, most often in children.
• What are the symptoms of the disease? — The main symptoms include abdominal pain, abdominal distension and anemia.
• How is ganglioneuroblastoma diagnosed? — Diagnostics includes laboratory tests, radiological methods and histological biopsy.
• How is ganglioneuroblastoma treated? — Treatment may include surgical resection, chemotherapy, and radiation therapy.
• What is the prognosis for patients with ganglioneuroblastoma? — The prognosis depends on the stage of the disease and the time of treatment; early diagnosis increases the chances of recovery.

Dr. Oleg Korzhikov recommends that parents pay attention to any changes in their children's health, such as unexplained weight loss, an enlarged abdomen, or pain in the abdominal area. He emphasizes the importance of early medical attention if symptoms are present that may indicate ganglioneuroblastoma. In addition, it is important for parents to know that observing parents of children with a genetic predisposition to tumors can increase their level of vigilance for possible symptoms even in adulthood.